TeraFab Win Adds Intel Foundry Credibility, but Commercial Scale Remains Unproven
Read source articleWhat happened
Intel has secured a deal to supply technology, IP, and manufacturing expertise to TeraFab, which an analyst cites as a credibility boost for its foundry arm. However, DeepValue's report notes Intel's external foundry business is minimal, with FY2025 revenue of only $307M and no significant commercial customers to date. The foundry segment continues to report heavy losses, around $2.5B per quarter in Q4'25, driven by the costly ramp of the 18A process. Market focus remains on Intel's ability to attract named external customers with committed volumes, a milestone critical for shifting revenue from government projects to commercial scale. While the TeraFab deal signals some external engagement, it does not address the core challenge of securing high-volume commercial commitments needed to improve profitability.
Implication
This deal may bolster Intel's foundry narrative by demonstrating external interest and technical capability, potentially easing near-term skepticism. Yet, it falls short of the 'significant external foundry customer' threshold highlighted in DeepValue's report, as external revenue remains dominated by government projects and losses persist. Investors must still monitor for concrete evidence of commercial volume ramps, which would improve utilization and reduce foundry losses. Without such progress, Intel's stock premium could erode as the 18A ramp continues to pressure margins. Thus, the implication is neutral to slightly positive but insufficient to change the cautious investment stance until more substantial customer wins emerge.
Thesis delta
The TeraFab win does not shift the core investment thesis, which hinges on Intel securing commercial external foundry customers to validate its foundry strategy and improve economics. It provides incremental credibility but does not change the financial reality of high losses or the absence of significant commercial revenue. Investors should maintain the 'WAIT' rating, as the thesis remains unchanged until named customer signings with committed volumes are disclosed.
Confidence
Moderate